Skip to main content
Evidence Snapshot

Xanthine dehydrogenase/oxidase

CHEMBL1929 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1929
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Xanthine dehydrogenase/oxidase as ChEMBL target CHEMBL1929, mapped to UniProt P47989. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Xanthine dehydrogenase/oxidase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1929
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47989
Xanthine dehydrogenase/oxidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Xanthine dehydrogenase/oxidase matters

As of 2026-09-13

Xanthine dehydrogenase/oxidase is reviewed as Xanthine dehydrogenase/oxidase (UniProt P47989); Xanthine dehydrogenase/oxidase shows approved-linked disease relevance led by hyperuricemia. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 1074 compounds, and 174 assays, with lead potency reaching pChEMBL 10.8.

Disease context
hyperuricemia

Xanthine dehydrogenase/oxidase shows approved-linked disease relevance led by hyperuricemia. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALLOPURINOL, FEBUXOSTAT, TOPIROXOSTAT.

Start review with hyperuricemia because it currently carries approved-linked support. Linked drugs include ALLOPURINOL, FEBUXOSTAT, TOPIROXOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 1074 compounds, and 174 assays for this target. The dominant activity type is IC50. CHEMBL5911881 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL5911881 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Xanthine dehydrogenase/oxidase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P47989, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hyperuricemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1074
Total Compounds
174
Total Assays
6
Approved Drugs
IC50: 1042.0, KI: 64.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5911881
 10.8 IC50 —
No preferred name
CHEMBL5395750
 10.7 IC50 —
No preferred name
CHEMBL5893388
 10.5 IC50 —
No preferred name
CHEMBL5753958
 10.4 IC50 —
No preferred name
CHEMBL5765459
 10.4 IC50 —

Approved Drugs

Structure Compound First Approval
FEBUXOSTAT
CHEMBL1164729
 2008
ALLOPURINOL
CHEMBL1467
 1966
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1929